BRAFV600E突变转移性结直肠癌:个性化治疗的当前进展和未来的前景
Stefania Napolitano1, Davide Ciardiello2, Eleonora Cioli1
1Department of Precision Medicine, The University of Campania Luigi Vanvitelli, Naples, Italy.
Cancer treatment reviews
|February 26, 2025
概括
在转移性结直肠癌 (mCRC) 中的BRAF V600E突变表明预后不佳. 新型向疗法正在出现,改变了这些患者的治疗格局.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 遗传学 是一个遗传学.
背景情况:
- BRAF V600E突变是转移性结直肠癌 (mCRC) 患者的一个子集的关键驱动因素.
- 这种突变与预后不佳和标准疗法受益有限有关.
- 分子分析的进步,包括下一代测序,已经在BRAF突变的mCRC中确定了可操作的目标.
研究的目的:
- 审查目前批准的BRAF V600E突变mCRC的治疗方法.
- 讨论针对性治疗时代BRAF突变mCRC的不断变化的治疗环境.
- 为了突出这一患者亚组的新治疗策略.
主要方法:
- 对已批准的治疗方法和新兴疗法的文献评论.
- 分析分子分析和下一代测序的影响.
- 讨论抵抗路径和组合策略.
主要成果:
- BRAF V600E突变标识了一个独特的mCRC亚组,预后不佳.
- 针对多个抗药性途径显示出改善疗效的希望.
- 对BRAF突变mCRC的治疗环境已经迅速发展,有了新的选择.
结论:
- BRAF V600E突变对mCRC患者管理有重大影响.
- 有针对性的分子疗法正在改变治疗方法.
- 新的策略为BRAF突变的mCRC患者提供了新的希望.
相关概念视频
Targeted Cancer Therapies
7.4K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.4K
Combination Therapies and Personalized Medicine
4.8K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.8K
Treatment Resistant Cancers
3.2K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.2K


